Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 May 15;101(10):2165–2173. doi: 10.1172/JCI1111

Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.

S Khosla 1, A A Hassoun 1, B K Baker 1, F Liu 1, N N Zein 1, M P Whyte 1, C A Reasner 1, T B Nippoldt 1, R D Tiegs 1, R L Hintz 1, C A Conover 1
PMCID: PMC508804  PMID: 9593772

Abstract

Hepatitis C-associated osteosclerosis (HCAO) is a rare disorder characterized by a marked increase in bone mass during adult life. Despite the rarity of HCAO, understanding the mediator(s) of the skeletal disease is of great interest. The IGFs-I and -II have potent anabolic effects on bone, and alterations in the IGFs and/or IGF-binding proteins (IGFBPs) could be responsible for the increase in bone formation in this disorder. Thus, we assayed sera from seven cases of HCAO for IGF-I, IGF-II, IGF-IIE (an IGF-II precursor), and IGFBPs. The distribution of the serum IGFs and IGFBPs between their ternary ( approximately 150 kD) and binary (approximately 50 kD) complexes was also determined to assess IGF bioavailability. HCAO patients had normal serum levels of IGF-I and -II, but had markedly elevated levels of IGF-IIE. Of the IGFBPs, an increase in IGFBP-2 was unique to these patients and was not found in control hepatitis C or hepatitis B patients. IGF-I and -II in sera from patients with HCAO were carried, as in the case of sera from control subjects, bound to IGFBP-3 in the approximately 150-kD complex, which is retained in the circulation. However, IGF-IIE was predominantly in the approximately 50-kD complex in association with IGFBP-2; this complex can cross the capillary barrier and access target tissues. In vitro, we found that IGF-II enhanced by over threefold IGFBP-2 binding to extracellular matrix produced by human osteoblasts and that in an extracellular matrix-rich environment, the IGF-II/IGFBP-2 complex was as effective as IGF-II alone in stimulating human osteoblast proliferation. Thus, IGFBP-2 may facilitate the targeting of IGFs, and in particular IGF-IIE, to skeletal tissue in HCAO patients, with a subsequent stimulation by IGFs of osteoblast function. Our findings in HCAO suggest a possible means to increase bone mass in patients with osteoporosis.

Full Text

The Full Text of this article is available as a PDF (250.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai T., Busby W., Jr, Clemmons D. R. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology. 1996 Nov;137(11):4571–4575. doi: 10.1210/endo.137.11.8895319. [DOI] [PubMed] [Google Scholar]
  2. Bagi C. M., Brommage R., Deleon L., Adams S., Rosen D., Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res. 1994 Aug;9(8):1301–1312. doi: 10.1002/jbmr.5650090820. [DOI] [PubMed] [Google Scholar]
  3. Baxter R. C. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Horm Res. 1996;46(4-5):195–201. doi: 10.1159/000185023. [DOI] [PubMed] [Google Scholar]
  4. Bell G. I., Merryweather J. P., Sanchez-Pescador R., Stempien M. M., Priestley L., Scott J., Rall L. B. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. 1984 Aug 30-Sep 5Nature. 310(5980):775–777. doi: 10.1038/310775a0. [DOI] [PubMed] [Google Scholar]
  5. Bergman D., Einhorn T. I., Forster G. Stone bone syndrome--diffuse sclerosis of bone: a newly described clinical disorder. Endocr Pract. 1996 Jul-Aug;2(4):296–296. doi: 10.4158/EP.2.4.296. [DOI] [PubMed] [Google Scholar]
  6. Beyer H. S., Anderson Q., Shih M. S., Parfitt A. M., Heath H., 3rd Diffuse osteosclerosis in intravenous drug abusers. Am J Med. 1993 Dec;95(6):660–662. doi: 10.1016/0002-9343(93)90364-u. [DOI] [PubMed] [Google Scholar]
  7. Beyer H. S., Parfitt A. M., Shih M. S., Anderson Q., Heath H., 3rd Idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res. 1990 Dec;5(12):1257–1263. doi: 10.1002/jbmr.5650051211. [DOI] [PubMed] [Google Scholar]
  8. Clemmons D. R., Snyder D. K., Busby W. H., Jr Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab. 1991 Oct;73(4):727–733. doi: 10.1210/jcem-73-4-727. [DOI] [PubMed] [Google Scholar]
  9. Conover C. A. A unique receptor-independent mechanism by which insulinlike growth factor I regulates the availability of insulinlike growth factor binding proteins in normal and transformed human fibroblasts. J Clin Invest. 1991 Oct;88(4):1354–1361. doi: 10.1172/JCI115441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Conover C. A. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology. 1992 Jun;130(6):3191–3199. doi: 10.1210/endo.130.6.1375895. [DOI] [PubMed] [Google Scholar]
  11. Daughaday W. H., Emanuele M. A., Brooks M. H., Barbato A. L., Kapadia M., Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1434–1440. doi: 10.1056/NEJM198812013192202. [DOI] [PubMed] [Google Scholar]
  12. Delany A. M., Rydziel S., Canalis E. Autocrine down-regulation of collagenase-3 in rat bone cell cultures by insulin-like growth factors. Endocrinology. 1996 Nov;137(11):4665–4670. doi: 10.1210/endo.137.11.8895331. [DOI] [PubMed] [Google Scholar]
  13. Diamond T., Depczynski B. Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone. 1996 Dec;19(6):679–683. doi: 10.1016/s8756-3282(96)00304-3. [DOI] [PubMed] [Google Scholar]
  14. Durham S. K., Kiefer M. C., Riggs B. L., Conover C. A. Regulation of insulin-like growth factor binding protein 4 by a specific insulin-like growth factor binding protein 4 proteinase in normal human osteoblast-like cells: implications in bone cell physiology. J Bone Miner Res. 1994 Jan;9(1):111–117. doi: 10.1002/jbmr.5650090115. [DOI] [PubMed] [Google Scholar]
  15. Ebeling P. R., Jones J. D., O'Fallon W. M., Janes C. H., Riggs B. L. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab. 1993 Nov;77(5):1384–1387. doi: 10.1210/jcem.77.5.8077337. [DOI] [PubMed] [Google Scholar]
  16. Ernst M., Rodan G. A. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology. 1990 Aug;127(2):807–814. doi: 10.1210/endo-127-2-807. [DOI] [PubMed] [Google Scholar]
  17. Feyen J. H., Evans D. B., Binkert C., Heinrich G. F., Geisse S., Kocher H. P. Recombinant human [Cys281]insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor I-stimulated proliferation and collagen synthesis in fetal rat calvariae. J Biol Chem. 1991 Oct 15;266(29):19469–19474. [PubMed] [Google Scholar]
  18. Ghiron L. J., Thompson J. L., Holloway L., Hintz R. L., Butterfield G. E., Hoffman A. R., Marcus R. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res. 1995 Dec;10(12):1844–1852. doi: 10.1002/jbmr.5650101203. [DOI] [PubMed] [Google Scholar]
  19. Gowan L. K., Hampton B., Hill D. J., Schlueter R. J., Perdue J. F. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology. 1987 Aug;121(2):449–458. doi: 10.1210/endo-121-2-449. [DOI] [PubMed] [Google Scholar]
  20. Harris S. A., Enger R. J., Riggs B. L., Spelsberg T. C. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res. 1995 Feb;10(2):178–186. doi: 10.1002/jbmr.5650100203. [DOI] [PubMed] [Google Scholar]
  21. Hassager C., Fitzpatrick L. A., Spencer E. M., Riggs B. L., Conover C. A. Basal and regulated secretion of insulin-like growth factor binding proteins in osteoblast-like cells is cell line specific. J Clin Endocrinol Metab. 1992 Jul;75(1):228–233. doi: 10.1210/jcem.75.1.1377704. [DOI] [PubMed] [Google Scholar]
  22. Hassoun A. A., Nippoldt T. B., Tiegs R. D., Khosla S. Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med. 1997 Jul;103(1):70–73. doi: 10.1016/s0002-9343(97)00139-3. [DOI] [PubMed] [Google Scholar]
  23. Hossenlopp P., Seurin D., Segovia-Quinson B., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 1986 Apr;154(1):138–143. doi: 10.1016/0003-2697(86)90507-5. [DOI] [PubMed] [Google Scholar]
  24. Jones J. I., Gockerman A., Busby W. H., Jr, Camacho-Hubner C., Clemmons D. R. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. 1993 May;121(3):679–687. doi: 10.1083/jcb.121.3.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kream B. E., Tetradis S., Lafrancis D., Fall P. M., Feyen J. H., Raisz L. G. Modulation of the effects of glucocorticoids on collagen synthesis in fetal rat calvariae by insulin-like growth factor binding protein-2. J Bone Miner Res. 1997 Jun;12(6):889–895. doi: 10.1359/jbmr.1997.12.6.889. [DOI] [PubMed] [Google Scholar]
  26. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997 Feb 27;336(9):633–640. doi: 10.1056/NEJM199702273360907. [DOI] [PubMed] [Google Scholar]
  27. LeRoith D., Clemmons D., Nissley P., Rechler M. M. NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med. 1992 May 15;116(10):854–862. doi: 10.7326/0003-4819-116-10-854. [DOI] [PubMed] [Google Scholar]
  28. Liu F., Baker B. K., Powell D. R., Hintz R. L. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids. J Clin Endocrinol Metab. 1993 May;76(5):1095–1100. doi: 10.1210/jcem.76.5.8496298. [DOI] [PubMed] [Google Scholar]
  29. Liu F., Baxter R. C., Hintz R. L. Characterization of the high molecular weight insulin-like growth factor complex in term pregnancy serum. J Clin Endocrinol Metab. 1992 Nov;75(5):1261–1267. doi: 10.1210/jcem.75.5.1385469. [DOI] [PubMed] [Google Scholar]
  30. Mohnike K., Kluba U., Blum W. F., Aumann V., Vorwerk P., Mittler U. Serumkonzentrationen der insulinähnlichen Wachstumsfaktoren (IGF)-I und IGF-II sowie der IGF Bindungsproteine (IGFBP)-2 und IGFBP-3 bei 49 Kindern mit ALL, NHL oder soliden Tumoren. Klin Padiatr. 1995 Jul-Aug;207(4):225–229. doi: 10.1055/s-2008-1046545. [DOI] [PubMed] [Google Scholar]
  31. Narusawa K., Nakamura T., Suzuki K., Matsuoka Y., Lee L. J., Tanaka H., Seino Y. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res. 1995 Dec;10(12):1853–1864. doi: 10.1002/jbmr.5650101204. [DOI] [PubMed] [Google Scholar]
  32. Powell D. R., Rosenfeld R. G., Baker B. K., Liu F., Hintz R. L. Serum somatomedin levels in adults with chronic renal failure: the importance of measuring insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed uremic serum. J Clin Endocrinol Metab. 1986 Nov;63(5):1186–1192. doi: 10.1210/jcem-63-5-1186. [DOI] [PubMed] [Google Scholar]
  33. Prosser C. G., Schwander J. Influence of insulin-like growth factor-binding protein-2 on plasma clearance and transfer of insulin-like growth factors-I and -II from plasma into mammary-derived lymph and milk of goats. J Endocrinol. 1996 Jul;150(1):121–127. doi: 10.1677/joe.0.1500121. [DOI] [PubMed] [Google Scholar]
  34. Raisz L. G., Fall P. M., Gabbitas B. Y., McCarthy T. L., Kream B. E., Canalis E. Effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: role of insulin-like growth factor-I. Endocrinology. 1993 Oct;133(4):1504–1510. doi: 10.1210/endo.133.4.7691577. [DOI] [PubMed] [Google Scholar]
  35. Rinderknecht E., Humbel R. E. Primary structure of human insulin-like growth factor II. FEBS Lett. 1978 May 15;89(2):283–286. doi: 10.1016/0014-5793(78)80237-3. [DOI] [PubMed] [Google Scholar]
  36. Rinderknecht E., Humbel R. E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978 Apr 25;253(8):2769–2776. [PubMed] [Google Scholar]
  37. Robey P. G., Termine J. D. Human bone cells in vitro. Calcif Tissue Int. 1985 Sep;37(5):453–460. [PubMed] [Google Scholar]
  38. Rotwein P. Two insulin-like growth factor I messenger RNAs are expressed in human liver. Proc Natl Acad Sci U S A. 1986 Jan;83(1):77–81. doi: 10.1073/pnas.83.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Scharf J. G., Schmitz F., Frystyk J., Skjaerbaek C., Moesus H., Blum W. F., Ramadori G., Hartmann H. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol. 1996 Nov;25(5):689–699. doi: 10.1016/s0168-8278(96)80240-6. [DOI] [PubMed] [Google Scholar]
  40. Schmid C., Rutishauser J., Schläpfer I., Froesch E. R., Zapf J. Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis? Biochem Biophys Res Commun. 1991 Aug 30;179(1):579–585. doi: 10.1016/0006-291x(91)91410-e. [DOI] [PubMed] [Google Scholar]
  41. Shaker J. L., Reinus W. R., Whyte M. P. Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab. 1998 Jan;83(1):93–98. doi: 10.1210/jcem.83.1.4521. [DOI] [PubMed] [Google Scholar]
  42. Tally M., Eriksson U., Thorén M., Brismar K., Hall K. Immunoreactive proinsulin-like growth factor-II levels in healthy subjects, patients with growth hormone deficiency, and patients with type 1 diabetes: effects of insulin-like growth factor-I and insulin. J Clin Endocrinol Metab. 1994 Dec;79(6):1576–1581. doi: 10.1210/jcem.79.6.7989458. [DOI] [PubMed] [Google Scholar]
  43. Valenzano K. J., Heath-Monnig E., Tollefsen S. E., Lake M., Lobel P. Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants. J Biol Chem. 1997 Feb 21;272(8):4804–4813. doi: 10.1074/jbc.272.8.4804. [DOI] [PubMed] [Google Scholar]
  44. Villareal D. T., Murphy W. A., Teitelbaum S. L., Arens M. Q., Whyte M. P. Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med. 1992 Oct;93(4):371–381. doi: 10.1016/0002-9343(92)90165-8. [DOI] [PubMed] [Google Scholar]
  45. Whyte M. P., Reasner C. A., 2nd Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med. 1997 Feb;102(2):219–220. doi: 10.1016/s0002-9343(97)89507-1. [DOI] [PubMed] [Google Scholar]
  46. Whyte M. P., Teitelbaum S. L., Reinus W. R. Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res. 1996 Apr;11(4):554–558. doi: 10.1002/jbmr.5650110417. [DOI] [PubMed] [Google Scholar]
  47. Zapf J., Futo E., Peter M., Froesch E. R. Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest. 1992 Dec;90(6):2574–2584. doi: 10.1172/JCI116152. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES